Portage Biotech (NASDAQ:PRTG – Get Free Report) and Woodside Energy Group (NYSE:WDS – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.
Analyst Recommendations
This is a summary of current ratings for Portage Biotech and Woodside Energy Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Portage Biotech | 0 | 0 | 3 | 0 | 3.00 |
| Woodside Energy Group | 2 | 1 | 0 | 0 | 1.33 |
Portage Biotech currently has a consensus target price of $12.67, suggesting a potential upside of 429.99%. Given Portage Biotech’s stronger consensus rating and higher probable upside, research analysts clearly believe Portage Biotech is more favorable than Woodside Energy Group.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Portage Biotech | N/A | N/A | -$104.61 million | ($6.67) | -0.36 |
| Woodside Energy Group | $16.82 billion | 1.35 | $6.50 billion | N/A | N/A |
Woodside Energy Group has higher revenue and earnings than Portage Biotech.
Risk & Volatility
Portage Biotech has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Woodside Energy Group has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.
Institutional & Insider Ownership
2.0% of Portage Biotech shares are owned by institutional investors. Comparatively, 3.2% of Woodside Energy Group shares are owned by institutional investors. 42.1% of Portage Biotech shares are owned by insiders. Comparatively, 0.0% of Woodside Energy Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Portage Biotech and Woodside Energy Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Portage Biotech | N/A | -88.07% | -69.67% |
| Woodside Energy Group | N/A | N/A | N/A |
About Portage Biotech
Portage Biotech Inc., together with its subsidiaries, research and develops pharmaceutical and biotechnology products. The company's product pipeline includes IMM60, an iNKT cell activator that is in phase I clinical trial; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and INT230-6 for the treatment of tumors. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.
About Woodside Energy Group
Woodside Energy Group Ltd engages in the exploration, evaluation, development, production, marketing, and sale of hydrocarbons in Oceania, Africa, the Americas, Asia, and the Caribbean. The company produces liquefied natural gas, pipeline gas, condensate, natural gas liquids, and crude oil. It holds interests in the Pluto LNG, Northwest Shelf, Wheatstone and Julimar-Brunello, Bass Strait, Pyrenees FPSO, Macedon, Scarborough, Sangomar, Trion, Calypso, Browse, Wildling, Atlantis, Woodside Solar project, Sunrise and Troubadour, and Pluto Train 2 projects, as well as Liard basin. The company was formerly known as Woodside Petroleum Ltd and changed its name to Woodside Energy Group Ltd in May 2022. Woodside Energy Group Ltd was founded in 1954 and is headquartered in Perth, Australia.
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
